Key clinical point: Trifluridine/tipiracil had acceptable toxicities and efficacy in patients with mGC/GEJC with or without gastrectomy.
Major finding: In patients who had gastrectomies, the hazard ratio for OS of patients treated with FTD/TPI vs. placebo was 0.57 and the HR for PFS was 0.48.
Study details: Preplanned subgroup analysis of 507 patients with metastatic gastric or gastroesophageal junction cancer.
Disclosures: The study was funded by Taiho Oncology and Taiho Pharmaceutical Company. Dr. Islon reported grants and advisory role support from Taiho and others. Multiple coauthors had similar disclosures.
Ilson DH et al. JAMA Oncol. 2019 Oct 10. doi: 10.1001/jamaoncol.2019.3531.